If you had the misfortune to buy Novavax (NASDAQ: NVAX) stock in July 2015 and held on, around 90% of your investment would have been wiped out. Ouch. Even if you had bought the biotech stock at the beginning of 2017, you would be losing money.
With that context, the following statement might seem crazy: Novavax could be a gold mine for growth investors. But sometimes it’s the craziest ideas that prove to be the most successful. Here’s why the growth prospects for Novavax just might be much greater than many think.